Heching N - Search Results

1

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T. Abeliovich D, et al. Among authors: heching n. Am J Hum Genet. 1997 Mar;60(3):505-14. Am J Hum Genet. 1997. PMID: 9042909 Free PMC article.

2

[Genetic counseling for families at high cancer risk].

Sagi M, Heching N, Kadouri L, Abeliovich D, Zlotogora J, Bach G, Peretz T. Sagi M, et al. Among authors: heching n. Harefuah. 1996 Apr 1;130(7):441-6, 504. Harefuah. 1996. PMID: 8707209 Hebrew.

3

Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?

Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, Barak V. Nisman B, et al. Among authors: heching n. Cancer. 1998 May 15;82(10):1850-9. doi: 10.1002/(sici)1097-0142(19980515)82:10<1850::aid-cncr6>3.0.co;2-r. Cancer. 1998. PMID: 9587116 Clinical Trial.

4

Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers.

Kaduri L, Gibs M, Hubert A, Sagi M, Heching N, Lerer I, Uziely B, Weinberg N, Abeliovich D, Peretz T. Kaduri L, et al. Among authors: heching n. Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):75-80. doi: 10.1016/s0301-2115(98)00286-3. Eur J Obstet Gynecol Reprod Biol. 1999. PMID: 10428326

5

Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.

Nisman B, Amir G, Lafair J, Heching N, Lyass O, Peretz T, Barak V. Nisman B, et al. Among authors: heching n. Anticancer Res. 1999 Jul-Aug;19(4C):3549-52. Anticancer Res. 1999. PMID: 10629651

6

The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.

Nisman B, Heching N, Biran H, Barak V, Peretz T. Nisman B, et al. Among authors: heching n. Tumour Biol. 2006;27(1):8-16. doi: 10.1159/000090151. Epub 2005 Dec 8. Tumour Biol. 2006. PMID: 16340245

7

Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival.

Nisman B, Biran H, Heching N, Barak V, Ramu N, Nemirovsky I, Peretz T. Nisman B, et al. Among authors: heching n. Br J Cancer. 2008 Jan 15;98(1):77-9. doi: 10.1038/sj.bjc.6604157. Epub 2007 Dec 18. Br J Cancer. 2008. PMID: 18087272 Free PMC article.

8

The diagnostic and prognostic value of ProGRP in lung cancer.

Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. Nisman B, et al. Among authors: heching n. Anticancer Res. 2009 Nov;29(11):4827-32. Anticancer Res. 2009. PMID: 20032442 Free article.

9

Cytokeratin markers in malignant pleural mesothelioma.

Nisman B, Barak V, Heching N, Kramer M, Reinus C, Lafair J. Nisman B, et al. Among authors: heching n. Cancer Detect Prev. 1998;22(5):416-21. doi: 10.1046/j.1525-1500.1998.00053.x. Cancer Detect Prev. 1998. PMID: 9727622

10

Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival.

Tahover E, Segal A, Isacson R, Rosengarten O, Grenader T, Gips M, Cherny N, Heching NI, Mesika L, Catane R, Gabizon A. Tahover E, et al. Among authors: heching ni. Anticancer Drugs. 2017 Aug;28(7):787-794. doi: 10.1097/CAD.0000000000000514. Anticancer Drugs. 2017. PMID: 28562379

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page